Login to Your Account

Other News To Note

Monday, January 3, 2011
Swedish Orphan Biovitrum AB, of Stockholm, Sweden, announced that it has returned full development rights for its immune thrombocytopenic purpura (ITP) treatment and for hemolytic disease in newborn (HDN) prophylaxis to Symphogen A/S, of Copenhagen, Denmark, co-developer of Sym001, which is currently in Phase II trials for treatment of ITP and in anti-D prophylaxis to prevent HDN.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription